Oscar Health

Oscar Health dropped sharply during regular trading, closing at $29.11, down 4.9% from the previous close of $30.61, after hitting a pre-market high of $31.83 and reversing steadily—a classic spike-and-retreat pattern. Despite a strong Q1 with net profit of $679.0 million (vs. a loss a year ago), EPS of $2.07 (up 125.6% YoY), and operating revenue of $4.65 billion (up 52.5% YoY), an ROE of 205.6% raised concerns over sustainability. The stock closed below its MA20 ($30.12), and continued to slide to $30.25 in post-market trading, indicating lingering selling pressure. It is now 12.1% off its 52-week high of $33.10, though still up 94.5% year-to-date and well above the 52-week low of $10.69.